The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo

Xenobiotica

Volumn 40, Issue 8, 2010, Pages 558-568

  Bergman, E ^a   Hedeland, M ^a,b   Bondesson, U ^a,b   Lennernas H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

BCRP; Biliary excretion; Drug transport; Inhibition of drug transport; OATP1B1; Pharmacokinetics; Porcine

Indexed keywords

IMATINIB; RIFAMPICIN; ROSUVASTATIN; BENZAMIDE DERIVATIVE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; BILIARY EXCRETION; BLOOD FLOW; BLOOD SAMPLING; CENTRAL VENOUS CATHETERIZATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG TRANSPORT; ENTEROHEPATIC CIRCULATION; FEMALE; HEPATIC VEIN; IN VIVO STUDY; INTRAHEPATIC BILE DUCT; INTRAJEJUNAL DRUG ADMINISTRATION; LIVER SINUSOID; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PORTAL VEIN; SWINE; TIME TO MAXIMUM PLASMA CONCENTRATION; BILE; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION;

SUIDAE; SUS;

ADMINISTRATION, ORAL; BENZAMIDES; BILE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; PIPERAZINES; PYRIMIDINES; RIFAMPIN; SULFONAMIDES;

EID: 77954634046     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.496498     Document Type: Article

References (58)

1. Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, Knutson L, Lennernäs H. (2006). Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci 29:205-214.
2. Bergman E, Lundahl A, Fridblom P, Hedeland M, Bondesson U, Knutson L, Lennernäs H. (2009). Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos 37:2349-2358.
3. Bergman E, Matsson EM, Hedeland M, Bondesson U, Knutson L, Lennernäs H. (2010). Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers. J Clin Pharmacol (In Press).
4. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brøsen K. (2004). Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60:109-114.
5. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K. (2004). Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942.
6. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. (2005). Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4:747-752.
7. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI. (1999). Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228.
8. Cui Y, König J, Keppler D. (2001). Vectorial transport by doubletransfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60:934-943.
9. Eisenblätter T, Galla HJ. (2002). A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 293:1273-1278.
10. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. (2000). Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
11. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. (1996). Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
12. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D. (2000). The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580.
13. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. (2004). Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34:961-971.
14. Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. (2008). Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 25:1851-1860.
15. Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist WF. (2009). Substrate-dependent breast cancer resistance protein (Bcrp1/ Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 37:560-570.
16. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. (1999). The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
17. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q. (2006). Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58: 374-383.
18. Hamada A, Miyano H, Watanabe H, Saito H. (2003). Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307:824-828.
19. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. (2005). Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 314: 876-882.
20. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
21. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333-2337.
22. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. (2008). Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141-3148.
23. Huang L, Wang Y, Grimm S. (2006). ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
24. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. (2006). Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756-1763.
25. Kaltenbach G, Levêque D, Peter JD, Salmon J, Elkhaili H, Cavalier A, Salmon Y, Monteil H, Jehl F. (1996). Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. Antimicrob Agents Chemother 40:2043-2046. (Pubitemid 26296244)
26. Kitamura S, Maeda K, Wang Y, Sugiyama Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
27. Lam JL, Shugarts SB, Okochi H, Benet LZ. (2006). Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther 319:864-870.
28. Lau YY, Huang Y, Frassetto L, Benet LZ. (2007). effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204.
29. Lau YY, Okochi H, Huang Y, Benet LZ. (2006). Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
30. Leveque D, Wisniewski S, Renault C, Peter JD, Le Corre P, Monteil H, Jehl F. (2003). The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. Anticancer Res 23:2741-2744.
31. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. (2003a). Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563.
32. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. (2003b). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822-2835.
33. Matsson P, Englund G, Ahlin G, Bergström CA, Norinder U, Artursson P. (2007). A global drug inhibition pattern for the human ATPbinding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 323:19-30.
34. Muenster U, Grieshop B, Ickenroth K, Gnoth MJ. (2008). Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25:2320-2326.
35. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. (2000). Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 68:495-500.
36. Nordgren A, Karlsson T, Wiklund L. (2002). Glutamine concentration and tissue exchange with intravenously administered alphaketoglutaric acid and ammonium: a dose-response study in the pig. Nutrition 18:496-504.
37. Olinga P, Elferink MG, Draaisma AL, Merema MT, Castell JV, Pérez G, Groothuis GM. (2008). Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 33:380-389.
38. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. (2009). The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/ BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40.
39. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P. (2008). Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 51:3275-3287.
40. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. (2004). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158-162.
41. Persson EM, Nordgren A, Forsell P, Knutson L, Ohgren C, Forssén S, Lennernäs H, Abrahamsson B. (2008). Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur J Pharm Sci 34:22-29.
42. Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, Lennernäs H. (2006). First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182-1189.
43. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. (2004). The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75: 455-463.
44. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177.
45. Sjödin E, Fritsch H, Eriksson UG, Logren U, Nordgren A, Forsell P, Knutson L, Lennernäs H. (2008). Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab Dispos 36:1519-1528.
46. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. (2000). Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
47. Thompson PD, Clarkson P, Karas RH. (2003). Statin-associated myopathy. JAMA 289:1681-1690.
48. Thörn HA, Hedeland M, Bondesson U, Knutson L, Yasin M, Dickinson P, Lennernäs H. (2009). Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. Drug Metab Dispos 37:2186-2196.
49. Tirona RG, Leake BF, Wolkoff AW, Kim RB. (2003). Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
50. van den Broek JM, Teunissen MW, Breimer DD. (1981). Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. Drug Metab Dispos 9:541-544.
51. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. (2007). Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81:414-419.
52. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328: 652-662.
53. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. (2002). Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36: 164-172.
54. Wolf KK, Vora S, Webster LO, Generaux GT, Polli JW, Brouwer KL. (2010). Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport Toxicol In Vitro 24:297-309.
55. Xia CQ, Liu N, Miwa GT, Gan LS. (2007). Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576-582.
56. Zhang W, Deng S, Chen XP, Zhou G, Xie HT, He FY, Cao D, Li YJ, Zhou HH. (2008). Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther 30:1283-1289.
57. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH. (2006). Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103.
58. Zheng HX, Huang Y, Frassetto LA, Benet LZ. (2009). Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78-85.